TORONTO and HOUSTON, TX, Oct. 31,
2017 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna"
or the "Company") (TSX: MDNA; OTCQX: MDNAF), a clinical stage
immuno-oncology company, today announced that Dr. Martin Bexon, MD, Head of Clinical Development
at Medicenna, will present results from earlier clinical trials at
the Cancer Prevention and Research Institute of Texas' ("CPRIT") Fifth Innovations in Cancer
Prevention and Research Conference to be held from November 13-14, 2017 in Austin, TX.
The poster presentation by Dr. Bexon will provide an overview of
the safety and efficacy results from previous Phase 1 and 2
clinical trials of the targeted immunotherapy, MDNA55, in 66
patients with recurrent glioblastoma (rGBM), the most common and
deadly form of brain cancer.
The details of the presentation are as follows:
Title:
|
Clinical Safety and
Efficacy of MDNA55: Results of 3 Studies in Recurrent Malignant
Gliomas
|
Date:
|
Tuesday, November 14,
2017
|
Time:
|
10:00 AM
|
Session:
|
Treatment and
Therapeutics
|
Session
ID:
|
Poster Group
B
|
Location:
|
Renaissance Arboretum
Hotel, Austin, TX
|
About Medicenna Therapeutics Corp.
Medicenna is a clinical stage immuno-oncology company developing
novel highly selective versions of IL-2, IL-4 and IL-13 Superkines™
and first in class Empowered Cytokines™ (ECs). Its wholly
owned subsidiary, Houston-based Medicenna BioPharma, is
specifically targeting the Interleukin-4 Receptor (IL4R), which is
over-expressed by at least 20 different types of cancer affecting
more than one million new cancer patients every year. Medicenna's
lead IL4-EC, MDNA55 is enrolling patients in a CPRIT funded Phase
2b clinical trial for rGBM at leading brain cancer centres in the
US. MDNA55 has completed 3 clinical trials in 72 patients,
including 66 adults with rGBM, demonstrated compelling efficacy and
obtained Fast-Track and Orphan Drug status from USFDA. Unlike most
other cancer therapies, Medicenna's IL4-ECs have the potential to
purge both the tumor and the immunosuppressive tumor
microenvironment, offering a unique treatment paradigm for a large
majority of cancer patients.
For more information, please visit www.medicenna.com.
This news release contains forward-looking statements
relating to the future operations of the Company and other
statements that are not historical facts. Forward-looking
statements are often identified by terms such as "will", "may",
"should", "anticipate", "expects" and similar expressions. All
statements other than statements of historical fact, included in
this release, including, without limitation, statements regarding
future plans and objectives of the Company and others are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Important
factors that could cause actual results to differ materially from
the Company's expectations include the risks detailed in the annual
information form of the Company dated June
15, 2017 and in other filings made by the Company with the
applicable securities regulators from time to time.
The reader is cautioned that assumptions used in the
preparation of any forward-looking information may prove to be
incorrect. Events or circumstances may cause actual results to
differ materially from those predicted, as a result of numerous
known and unknown risks, uncertainties, and other factors, many of
which are beyond the control of the Company. The reader is
cautioned not to place undue reliance on any forward-looking
information. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement. The
forward-looking statements contained in this news release are made
as of the date of this news release and the Company will update or
revise publicly any of the included forward-looking statements only
as expressly required by Canadian securities law.
SOURCE Medicenna Therapeutics Corp.